Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REDUCE: Dutasteride for Prostate Cancer Prevention
NCT00056407Phase 3Completed
- Sponsor
- GSK
- Start
- Mar 2003
- Primary completion
- Jan 2009
- Modality
- Small Molecules
- Countries
- 42
01
Overview
Phase 3, randomised, double-blind trial in prostate cancer (PCa) comparing Dutasteride Arm with Placebo Arm (2 arms). Primary endpoint: Number of Participants With Biopsy-detectable Prostate Cancer at 4 years. Started Mar 2003; status: completed.
02
Drugs
dutasteride
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00056407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00056407.